The State of Biosimilars: How We Got Here and What It Means for Practice
Two biosimilars are approved for use in retina by the US FDA\u2014and more will be approved in the coming years. What exactly are biosimilars? What benefit might they provide? And how confident are retina specialist that biosimilars will deliver safe, high-quality care?\xa0\n\nModerator John Kitchens, MD, sits down with retina specialists Carl Awh, MD, and Firas Rahhal, MD, to answer these questions, and to ask whether the economic realities of biosimilars make them a good choice for modern retina practices.\xa0\n\nThis podcast is editorially independent, supported with advertising by Cimerli.